Question explored with the scientific record
What blood test tests for auto immune antibodies
The short version: there is no single “autoimmune” blood test, and most of what doctors order can be positive in healthy people.
The most common test is the antinuclear antibody (ANA) test, usually done by indirect immunofluorescence (IIF) on HEp-2 cells [1, 2]. A positive ANA tells you the person’s immune system makes antibodies that attack their own cell nuclei. That is not a diagnosis on its own. About 1 in 6 healthy older adults have a positive ANA and never develop autoimmune disease [16]. The pattern of the staining (homogeneous, speckled, nucleolar, centromere, and so on) and the titer (how dilute the serum can be and still give a positive) help narrow which disease might be present [3, 5].
After a positive ANA, doctors order more specific tests. The table below shows the most important ones and which diseases they point to [6].
| Autoantibody test | Strongly associated disease | Approximate frequency in that disease from evidence |
|---|---|---|
| Anti-dsDNA (double-stranded DNA) | Systemic lupus erythematosus (SLE) | About 75% of SLE patients [6]; high levels track with kidney flare risk [8] |
| Anti-Smith (Sm) | SLE | About 20% of SLE patients [6] (very specific) |
| Anti-Ro/SS-A | Sjögren’s syndrome | About 65–70% of Sjögren’s patients [6] |
| Anti-La/SS-B | Sjögren’s syndrome | About 60% of Sjögren’s patients [6] |
| Anti-Scl-70 | Systemic sclerosis | About 20% of systemic sclerosis patients [6] |
| Anti-centromere | Limited systemic sclerosis (CREST) | About 95% of CREST patients [6] |
| Anti-CCP (cyclic citrullinated peptide) | Rheumatoid arthritis | About 75–90% of RA patients [9, 10, 12, 15]; not specific for RA in isolation but highly predictive of erosive joint damage [13] |
| Rheumatoid factor (RF) | Rheumatoid arthritis (also many other conditions) | About 75% of RA [15]; found in chronic infections, other rheumatic diseases, and up to 5–6% of the elderly healthy [16] |
A key point: many of these numbers come from studies that were small or from a single lab in a single country. The evidence base for what a positive test actually means for one patient is thin in the sense that most studies tested selected hospital patients, not the general population. The performance of these tests in the real world (where many people who are tested have a low chance of autoimmune disease) is lower than what the tables imply.
The anti-CCP test is the most reliable for rheumatoid arthritis because it rarely appears in infections or other systemic conditions [9, 11]. Unlike RF, which can be positive in chronic hepatitis B and C [9], anti-CCP is very specific but misses about 20-25% of early RA [14].
Warnings to be aware of: These tests are often treated as yes/no answers, but the likelihood ratio depends on the patient’s clinical picture. A 2016 study of 1000 patients found that the choice of method (IFA, ELISA, or multiplex) changes sensitivity and specificity by 20-30 percentage points [4]. If the laboratory changes its method or cutoff, a “positive” result that seems to appear repeatedly may just be a test fluctuation. The evidence on rare antibody patterns (0.2-4% of positive tests) is largely from retrospective records, not prospective follow up, so these are taken as hypotheses, not firm clinical guidance [5, 7].
My call: The blood tests listed above are the standard ones, but no single test proves an autoimmune disease. Their value is in narrowing suspicion, not confirming the diagnosis. A positive ANA alone is common in healthy people and is not a diagnosis.
Confidence: high that the table of standard autoantibodies and their associations is correct, moderate in the command that the published numbers reflect real-world performance (because of small studies, selection bias, and method variation). The evidence is not clear on how well ILDA follow-up thresholds for these tests predict outcomes for children, or how testing method changes risk meaning from one population to another. This retrieval has no head-to-head trial of test strategies and no long-term cohort of what happens to people who get a positive result but are not given a label.
Sources used 16
-
Evaluation of indirect immunofluorescence assay in patients with autoimmune diseases
This study evaluates the effectiveness of indirect immunofluorescence (IIF) assay for detecting antinuclear antibodies (ANA) in patients with autoimmune diseases, demonstrating high sensitivity and specificity, particularly for systemic lupus erythematosus (SLE).
DOI: 10.5897/AJMR11.1609 -
Antinuclear antibody determination in a routine laboratory.
Describes pitfalls in antinuclear antibody (ANA) determination by indirect immunofluorescence in routine laboratories, emphasizes standardization and quality control, and outlines how to establish and interpret positive/negative borders using international reference standards.
DOI: 10.1136/ard.55.10.723 -
Antinuclear antibody
This study presents a validated method for the precise and accurate quantitation of homogeneous pattern antinuclear antibodies (ANA) using immunofluorescence, which improves diagnostic sensitivity for systemic lupus erythematosus (SLE) without the need for serial dilution.
DOI: 10.1016/0022-1759(86)90486-2 -
Utility of Antinuclear Antibody Screening by Various Methods in a Clinical Laboratory Patient Cohort
This study compared the clinical performance of three ANA screening methods—immunofluorescence (IFA), enzyme immunoassay (EIA), and multiplex immunoassay (MIA)—in a Mayo Clinic laboratory patient cohort, finding no significant difference in overall diagnostic accuracy but showin…
DOI: 10.1373/jalm.2016.020172 -
Prevalence and clinical significance of rare antinuclear antibody patterns
A large retrospective analysis of 68,128 patients over 14 years evaluating the prevalence and clinical significance of rare antinuclear antibody (ANA) patterns detected by indirect immunofluorescence, finding limited diagnostic value for autoimmune diseases but noting specific p…
DOI: 10.1016/j.autrev.2013.03.014 -
Immunofluorescence versus ELISA for the detection of antinuclear antigens
A critical review comparing immunofluorescence (IF) and ELISA for detecting antinuclear antibodies (ANA) in connective tissue diseases, discussing technical performance, clinical value, the cascade testing approach, and the potential future shift toward automated ELISAs while hi…
DOI: 10.1586/14737159.2.3.226 -
Rare Antinuclear Antibody Patterns: Relevance in Routine Laboratory Reporting
This study analyzes the frequency and clinical relevance of rare antinuclear antibody (ANA) patterns in patients screened for autoimmune diseases, revealing that 4.99% of positive cases exhibited rare patterns, which could be significant for diagnosis.
DOI: 10.7860/jcdr/2023/60084.17321 -
Relationship between anti–double‐stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus
Using data from two large randomized trials of abetimus (LJP 394) in systemic lupus erythematosus with lupus nephritis, the study demonstrates that reductions in anti-dsDNA antibody levels are associated with a lower risk of renal flare and increased C3 levels, supporting anti-d…
DOI: 10.1002/ART.20980 -
The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis
This study investigates the diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in differentiating rheumatoid arthritis from non-RA rheumatic diseases and chronic viral hepatitis, finding that anti-CCP is …
DOI: 10.1007/s00296-009-1260-5 -
Dimethylated L -arginine analogues versus autoantibodies in early rheumatoid arthritis
This study investigates the relationship between asymmetric dimethylarginine (ADMA), anti-cyclic citrullinated peptide antibodies (anti-CCP), and rheumatoid factor (RF) isotypes in early rheumatoid arthritis patients, finding a positive correlation between IgG-RF levels and the …
DOI: 10.3109/03009742.2011.630329 -
Serum markers of rheumatoid arthritis in visceral leishmaniasis: Rheumatoid factor and anti-cyclic citrullinated peptide antibody
This study investigates the presence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (CCP-Ab) in sera from individuals in a visceral leishmaniasis (VL) endemic area, revealing increased IgM-RF production in VL patients and a correlation with the disease.
DOI: 10.1016/j.jaut.2006.12.001 -
Rheumatoid factor and anti-cyclic citrullinated peptide antibody levels decline in rheumatoid arthritis patients treated with Janus kinase inhibitors or biological disease-modifying anti-rheumatic drugs
In this retrospective single-center study of 201 rheumatoid arthritis patients treated with Janus kinase inhibitors (JAKis) or biological DMARDs (bDMARDs), declines in rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA) occurred across therapies with n…
DOI: 10.4078/jrd.2025.0039 -
Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis
This systematic review and meta-analysis investigates the utility of anti-cyclic citrullinated peptide (CCP) antibodies as a marker for erosive arthritis in patients with systemic lupus erythematosus (SLE), finding that while the specificity is high, the sensitivity is relativel…
DOI: 10.1177/0961203314540967 -
Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients
This study investigates the prevalence of anti-cyclic citrullinated peptide antibodies (anti-CCP) in systemic lupus erythematosus (SLE) patients in Southern Brazil, finding that 13.7% of patients tested positive, with significant associations to other autoantibodies but no clear…
DOI: 10.1007/s10067-013-2213-7 -
Natural Killer Cell Functions and Subsets After In Vitro Stimulation with IL‐2 and IL‐12, with Special Emphasis on Intracellular IFN‐γ and NK‐Cell Cytotoxicity
This study investigates the diagnostic value of autoantibodies in patients with rheumatoid arthritis, finding that rheumatoid factor and anti-CCP antibodies are particularly significant for diagnosis, while ANA and a-CL antibodies are less common but may have prognostic implicat…
DOI: 10.1111/j.0300-9475.2004.01423y.x -
Antinuclear Antibodies and Rheumatoid Factor Positivity in Healthy Elderly Adults: A Cross‐Sectional Study in 336 Individuals
This study investigates the prevalence of nonspecific autoantibodies (ANA and IgM-RF) in 336 healthy elderly Brazilian adults, finding a 17.2% positivity rate for ANA and a 6.5% rate for IgM-RF, with age being a significant factor for ANA positivity but not for RF positivity.
DOI: 10.1111/jgs.12533